BUDESONIDE ORODISPERSIBLE TABLETS ARE HIGHLY EFFECTIVE FOR RE-INDUCTION OF CLINICAL REMISSION IN RELAPSING ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE EOS-2 TRIAL

Christoph Schlag  ¹     Alex Straumann  ²     Stephan Miehlke  ³     Luc Biedermann  ⁴     Cecilio Santander Vaquero  ⁵     Constanza Ciriza De Los Ríos  ⁶     Christoph Schmöcker  ⁷     Ahmed Madisch  ⁸     Petr Hruz  ⁹     Jamal Hayat  ¹⁰     Ulrike von Arnim  ¹¹     Albert Jan Bredenoord  ¹²     Stefan Schubert  ¹³     Ralph Mueller  ¹⁴     Roland Greinwald  ¹⁴     Alfredo J. Lucendo  ¹⁵     Alain M. Schoepfer  ¹⁶     Stephen E. Attwood  ^17    
1 Klinikum rechts der Isar - TU München, München, Germany
² Swiss EoE Research Network, Olten, Switzerland
³ Center for Digestive Diseases, Internal Medicine Center Eppendorf, Hamburg, Germany
⁴ University Hospital Zurich, Zurich, Switzerland
⁵ Hospital Universitario de la Princesa, Madrid, Spain
⁶ Hospital 12 de Octubre, Madrid, Spain
⁷ Sana Klinikum Lichtenberg, Berlin, Germany
⁸ CRH Clinic Hannover, Hannover, Germany
⁹ University Hospital Basel, Basel, Switzerland
¹⁰ St. George`s University Hospitals NHS Trust, London, United Kingdom
¹¹ University Hospital Magdeburg, Madgeburg, Germany
¹² Academisch Med. Centrum Amsterdam, Amsterdam, Netherlands
¹³ Gastroenterologist in Private Practice, Berlin, Germany
¹⁴ Dr. Falk Pharma GmbH, Freiburg, Germany
¹⁵ Hospital General de Tomelloso, Tomelloso, Spain
¹⁶ University Hospital (CHUV), Lausanne, Switzerland
¹⁷ Durham University, North Tyneside, United Kingdom

Session
Novel insights in a new disease: Eosinophilic oesophagitis

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)